SI2114405T1 - Kokristalna oblika "a" metilparabena (4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il)-(5-metan- sulfonil-2-((s)-2,2,2-trifluoro-1-metil-etoksi)-fenil)-metanona - Google Patents

Kokristalna oblika "a" metilparabena (4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il)-(5-metan- sulfonil-2-((s)-2,2,2-trifluoro-1-metil-etoksi)-fenil)-metanona

Info

Publication number
SI2114405T1
SI2114405T1 SI200731644T SI200731644T SI2114405T1 SI 2114405 T1 SI2114405 T1 SI 2114405T1 SI 200731644 T SI200731644 T SI 200731644T SI 200731644 T SI200731644 T SI 200731644T SI 2114405 T1 SI2114405 T1 SI 2114405T1
Authority
SI
Slovenia
Prior art keywords
methanone
piperazin
methanesulfonyl
trifluoro
pyridin
Prior art date
Application number
SI200731644T
Other languages
English (en)
Inventor
Andre Bubendorf
Annette Deynet-Vucenovic
Ralph Diodone
Olaf Grassmann
Kai Lindenstruth
Emmanuel Pinard
Franziska E. Rohrer
Urs Schwitter
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2114405(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI2114405T1 publication Critical patent/SI2114405T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
SI200731644T 2006-12-28 2007-12-18 Kokristalna oblika "a" metilparabena (4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il)-(5-metan- sulfonil-2-((s)-2,2,2-trifluoro-1-metil-etoksi)-fenil)-metanona SI2114405T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28
EP07857734.3A EP2114405B1 (en) 2006-12-28 2007-12-18 methylparaben cocrystal form "A" of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2- ((S) -2,2,2-trifluoro- 1 -methyl-ethoxy) -phenyl] -methanone
PCT/EP2007/064104 WO2008080821A1 (en) 2006-12-28 2007-12-18 Crystalline forms glyt1

Publications (1)

Publication Number Publication Date
SI2114405T1 true SI2114405T1 (sl) 2015-06-30

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731644T SI2114405T1 (sl) 2006-12-28 2007-12-18 Kokristalna oblika "a" metilparabena (4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il)-(5-metan- sulfonil-2-((s)-2,2,2-trifluoro-1-metil-etoksi)-fenil)-metanona

Country Status (33)

Country Link
US (5) US20080214561A1 (sl)
EP (1) EP2114405B1 (sl)
JP (1) JP4799666B2 (sl)
KR (1) KR101130146B1 (sl)
CN (1) CN101573114A (sl)
AR (1) AR064545A1 (sl)
AU (1) AU2007341356B2 (sl)
BR (1) BRPI0720829B8 (sl)
CA (1) CA2673667A1 (sl)
CL (1) CL2007003830A1 (sl)
CO (1) CO6190613A2 (sl)
CR (1) CR10846A (sl)
CY (1) CY1116350T1 (sl)
DK (1) DK2114405T3 (sl)
EC (1) ECSP099471A (sl)
ES (1) ES2535040T3 (sl)
HR (1) HRP20150573T1 (sl)
HU (1) HUE025032T2 (sl)
MA (1) MA31029B1 (sl)
MX (1) MX2009006859A (sl)
MY (1) MY188367A (sl)
NO (1) NO342150B1 (sl)
NZ (1) NZ577502A (sl)
PE (1) PE20081556A1 (sl)
PL (1) PL2114405T3 (sl)
PT (1) PT2114405E (sl)
RS (1) RS53910B1 (sl)
RU (1) RU2463295C2 (sl)
SI (1) SI2114405T1 (sl)
TW (1) TWI388552B (sl)
UA (1) UA100232C2 (sl)
WO (1) WO2008080821A1 (sl)
ZA (1) ZA200904423B (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY188367A (en) 2006-12-28 2021-12-06 Hoffmann La Roche Crystalline forms glyt1
EP2400848A4 (en) 2009-02-26 2012-07-25 Thar Pharmaceuticals Inc CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
AU2013265472A1 (en) * 2012-05-25 2014-12-04 Basf Se Crystalline form B of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
CA3166938A1 (en) 2020-01-09 2021-07-15 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
CN115315299B (zh) * 2020-07-13 2024-06-04 日本碍子株式会社 精制方法
AU2022273051A1 (en) * 2021-05-14 2023-12-07 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
AU2022283357A1 (en) * 2021-05-27 2023-12-07 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
KR100774622B1 (ko) * 2003-08-11 2007-11-08 에프. 호프만-라 로슈 아게 Ｏｒ-치환된 페닐 그룹을 갖는 피페라진 및 ｇｌｙｔ1억제제로서 그의 용도
MY188367A (en) 2006-12-28 2021-12-06 Hoffmann La Roche Crystalline forms glyt1

Also Published As

Publication number Publication date
US20130197225A1 (en) 2013-08-01
JP2010514725A (ja) 2010-05-06
AR064545A1 (es) 2009-04-08
PL2114405T3 (pl) 2015-08-31
US20100311971A1 (en) 2010-12-09
PE20081556A1 (es) 2008-11-28
RU2009124113A (ru) 2011-02-10
BRPI0720829A2 (pt) 2014-02-25
TWI388552B (zh) 2013-03-11
NO342150B1 (no) 2018-04-03
PT2114405E (pt) 2015-06-02
AU2007341356A1 (en) 2008-07-10
TW200833677A (en) 2008-08-16
RU2463295C2 (ru) 2012-10-10
US20120309969A1 (en) 2012-12-06
CY1116350T1 (el) 2017-03-15
CA2673667A1 (en) 2008-07-10
MY188367A (en) 2021-12-06
US20110295007A1 (en) 2011-12-01
US20080214561A1 (en) 2008-09-04
BRPI0720829B8 (pt) 2021-05-25
MA31029B1 (fr) 2009-12-01
CO6190613A2 (es) 2010-08-19
NZ577502A (en) 2012-02-24
EP2114405B1 (en) 2015-03-11
MX2009006859A (es) 2009-07-03
KR20090094166A (ko) 2009-09-03
US8039473B2 (en) 2011-10-18
HRP20150573T1 (en) 2015-07-03
JP4799666B2 (ja) 2011-10-26
BRPI0720829B1 (pt) 2020-04-07
CL2007003830A1 (es) 2008-07-11
ZA200904423B (en) 2010-05-26
CR10846A (es) 2009-08-12
AU2007341356B2 (en) 2013-08-29
EP2114405A1 (en) 2009-11-11
UA100232C2 (uk) 2012-12-10
KR101130146B1 (ko) 2012-03-28
ECSP099471A (es) 2009-07-31
HUE025032T2 (en) 2016-02-29
ES2535040T3 (es) 2015-05-04
NO20092358L (no) 2009-06-22
RS53910B1 (en) 2015-08-31
DK2114405T3 (en) 2015-04-07
WO2008080821A1 (en) 2008-07-10
CN101573114A (zh) 2009-11-04

Similar Documents

Publication Publication Date Title
SI2114405T1 (sl) Kokristalna oblika "a" metilparabena (4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il)-(5-metan- sulfonil-2-((s)-2,2,2-trifluoro-1-metil-etoksi)-fenil)-metanona
IL238068A0 (en) New therapeutic uses of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine
HK1171951A1 (en) 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment 5-ht3 5-ht1a 1-[2-(24-)-]
ZA200803926B (en) 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-D]imidazoles as MPGES-1 inhibitors
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
WO2006067103A3 (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
IL192242A0 (en) Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides
EP1828143A4 (en) 1H-PHENANTHRO [9,10-D] IMIDAZOLES SUBSTITUTED INTO 2 BY PHENYL OR HETEROCYCLE AS INHIBITORS OF MPGES-1
CU24179B1 (es) SALES DE ÁCIDO MALEICO Y DE ÁCIDO SULFÚRICO DE (R)-3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CICLOPENTILPROPANITRILO
EP1870401A4 (en) SUBSTITUTE DERIVATIVE PIPERAZINE IN 1,4
PL2203444T3 (pl) Stałe postacie (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(O-metylo-1H-pirazol-1-ilo)fenylo)-2,2,2-trifluoroetoksy)pirymidyn-4-ylo)fenylo)propionianu etylu
WO2003093269A3 (de) Substituierte pyrazolo-pyrimidin-4-one
WO2008123469A1 (ja) ６員環アミド化合物およびその用途
WO2006072393A3 (de) Sulfonylpyrrolidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2005105096A3 (en) Fused heterocyclic compounds
HRP20130819T1 (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
WO2005105749A3 (en) Process for making montelukast and intermediates therefor
WO2009068463A3 (en) Process for the preparation of isoindole derivatives as well as a process for the preparation of their intermediates
IL227950A0 (en) Crystalline and amorphous forms of -5 amino-1-[2,6]-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1-h-pyrazole-3-carbonitrile
DK1861389T3 (da) 7-(2-(4-(3-triflourmethylphenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl)isoquinoleinbesylatsalt
SI1505066T1 (sl) Polimorf 4-(2-(4-(1-(2-etoksietil)-1h-benzimidazol-2-il) -1-piperidinil)-alfa, alfa-dimetil-benzenocetne kisline
EP1992613A4 (en) PROCESS FOR PRODUCTION OF 3,4-DISUBSTITUTED PYRROLIDINE DERIVATIVE AND INTERMEDIATE PRODUCTION METHOD
WO2007039117A3 (en) A process for the preparation of sartan derivatives and intermediates useful in such process
ZA200801813B (en) Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-(1,8)naphthyridin-2-one
WO2009147389A3 (en) Processes for the synthesis of levocetirizine and intermediates for use therein